Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I
- 25 May 2001
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (11), 1411-1415
- https://doi.org/10.1016/s0960-894x(01)00240-2
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Inhibitors of protein prenylation 2000Expert Opinion on Therapeutic Patents, 2000
- Anticancer drug targets: growth factors and growth factor signalingJournal of Clinical Investigation, 2000
- Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic DevelopmentJournal of Clinical Oncology, 1999
- N-Arylpiperazinone Inhibitors of Farnesyltransferase: Discovery and Biological ActivityJournal of Medicinal Chemistry, 1999
- Farnesyl Protein Transferase Inhibitors and Other Therapies Targeting the Ras Signal Transduction PathwayInvestigational New Drugs, 1999
- Farnesyltransferase inhibitors: targeting the molecular basis of cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1999
- Efficient synthesis of N-arylpiperazinones via a selective intramolecular Mitsunobu cyclodehydrationTetrahedron Letters, 1998
- Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenograftsOncogene, 1998
- K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase InhibitorsJournal of Biological Chemistry, 1997
- Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.Proceedings of the National Academy of Sciences, 1992